mTOR inhibitor-8 is a potent mTOR inhibitor and autophagy inducer with antiviral and antitumor activity. mTOR inhibitor-8 inhibits the growth of A549 cells, which can be used to study non-small cell lung cancer.

mTOR inhibitor-8 (Compound 5e; 0.1-10 μM) suppresses the growth of A549 cells in a dose-dependent manner after 24 and 48 hours of treatment[1].
mTOR inhibitor-8 induces autophagy in an mTOR-dependent manner. At a concentration of 10 μM, mTOR inhibitor-8 induces autophagy in a time-dependent manner (3-24 hours), leading to enhanced levels of LC3B-II[1].At a concentration of 10 μM for 3-24 hours, mTOR inhibitor-8 reduces the phosphorylation of RPS6KB1 (ribosomal protein S6 kinase) and EIF4EBP1 (eukaryotic translation initiation factor 4E-binding protein 1), two essential substrates of mTOR[1].

In vivo, mTOR inhibitor-8 effectively inhibits tumor growth at concentrations of 25 and 50 μM for a duration of 6 days, without adversely affecting angiogenesis in the normal chick chorioallantoic membrane [1].